Evotec SE 2021 AR2
The report outlines Evotec's financial and operational performance for the fiscal year 2021, highlighting the introduction of its strategic framework, Action Plan 2025. The company achieved significant growth, with group revenues increasing by 23% to ’618.0 million, driven by strong base business and milestone payments. Key milestones included the opening of the first J.POD biologics manufacturing facility in Redmond, Washington, and the expansion of strategic partnerships with Bristol Myers Squibb and Takeda. Evotec also successfully completed a secondary listing on NASDAQ, raising gross proceeds of $500 million to fund its global infrastructure expansion.
Company: Evotec SE
Sector: Manufacturing
Country: Germany
Year: 2021
Type: AR2
Pages: 139
Back to company
Evotec SE
Annual Report
The report outlines Evotec's financial and operational performance for the fiscal year 2021, highlighting the introduction of its strategic framework, Action Plan 2025. The company achieved significant growth, with group revenues increasing by 23% to ’618.0 million, driven by strong base business and milestone payments. Key milestones included the opening of the first J.POD biologics manufacturing facility in Redmond, Washington, and the expansion of strategic partnerships with Bristol Myers Squibb and Takeda. Evotec also successfully completed a secondary listing on NASDAQ, raising gross proceeds of $500 million to fund its global infrastructure expansion.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2021
Reporting Period
Jan 1, 2021 - Dec 31, 2021
Fiscal Year
2021
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Assurance
Assurance Provider
Assurance Standard
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Women in Management
Employees